Delcath Systems

Pharmaceutical ManufacturingNew York, United States51-200 Employees

Delcath Systems is a specialty pharmaceutical and medical device company focused on treating primary and metastatic liver cancers. Its Melphalan/HDS system delivers high-dose chemotherapy to the liver while limiting systemic exposure, using Melphalan Hydrochloride for Injection with the Delcath Hepatic Delivery System. In Europe, the CHEMOSAT Delivery System for Melphalan is CE-marked, while in the United States Melphalan/HDS is in late-stage clinical development; since launch, more than 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers.

The company is based in New York City, New York, and operates in interventional oncology with a focus on liver-directed therapy. In 2026 it received a Patient Impact Award at the Life Science Industry Awards, and its strategy includes expanding clinical adoption in major European markets and pursuing orphan indications such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Sign up for free to view info

Email Format Employee directory